Key Takeaways
- Broad-based 23% 9M topline growth: All three verticals contributed, with CDMO surging 44% YoY in Q3 on new customers and deeper wallet share, not a one-off.
- Injectable facility on track, returns unquantified: Mechanical completion done; commercial production targeted by end-FY24, but management defers any utilization or P&L assessment to three quarters into FY25.
- Trade generics is the blue-sky bet: YTD growth at 28% on a ~₹120 cr base; management sees no fundamental growth ceiling until ~₹300 cr and a long-term path toward ₹2,000 cr.
- Management declined to reaffirm or replace old FY27 guidance: The original targets are "ahead in some cases and behind in some cases," and no new forward numbers were offered.
- What to watch next quarter: Injectable facility commercialization timing, any inorganic move on dosage forms, and whether CDMO momentum sustains without a seasonal tailwind.
CDMO: The Quarter's Engine
- 44% YoY growth, organic and broad: Driven by new customer additions, new products with existing customers, quality improvements, and a strengthened business development team. Management explicitly ruled out lumpy revenue or dependence on any single product or account.
- Schedule M as a moat: Windlas is already compliant across all facilities, which is generating customer momentum as the industry adjusts. New capacity expansions are being built to future Schedule M standards.
- No acute-season lift: The company does not carry antibiotics, so the quarter's jump was not driven by the acute season. Winter products contributed but were not the decisive factor.
- Customer concentration stable: Top 10 accounts at ~40%, top 20 at ~45%, consistent with prior periods. No one or two product additions drove the quarter.
- Employee cost rise framed as investment: The Q3 increase reflects ESOP charges, leadership hires, and variable incentives. Management views this as capacity-building that has already supported margin delivery.
Komal Gupta: "While we show it in opex, for us, it is investment because we will be able to deliver the kind of numbers that we have been delivering through motivation of the employees."
Trade Generics: The Blue-Ocean Bet
- 28% YTD growth on a small base: Quarterly growth can be lumpy due to tenders and institutional orders; management says the YTD view is the right one. At a ~₹120 cr run rate, the base is still small.
- No growth ceiling until ~₹300 cr: Management stated there is no fundamental limitation on the growth rate up to that threshold, and large trade generic companies reach ~₹2,000 cr, a goal Windlas sees as attainable.
- Market-following portfolio strategy: In the Northern Belt, the portfolio skews toward primary care (antibiotics, pain, respiratory, gastroenterology). As distribution expands into Southern states, diabetes and cardiovascular products are being added. The strategy is to follow market demand rather than push a uniform national portfolio.
- Rural distribution thesis: The branded generic model struggles in areas without physicians, where the chemist is the dispenser. Windlas positions trade generics as accessible, affordable medication for rural hinterland markets.
Hitesh Windlass: "the branded generic model essentially not being able to deliver to this space because, you know, physicians are not there and the chemist is the dispenser."
Injectable Facility: Built, Not Yet Proven
- Mechanical completion achieved end-Q2 FY24: The ~₹50 cr facility is now being shown to customers. Product portfolio has been identified, and it will serve all three verticals: trade generics, CDMO, and exports.
- Commercial production targeted by end-FY24: Management asks investors to evaluate capacity utilization, turnover, and bottom-line contribution three quarters into FY25, not sooner.
- Quality as the strategic wedge: Management believes the facility's quality standard will be a decisive competitive advantage in injectables, a segment where quality failures carry severe consequences.
- Export registrations are a multi-year tail: Registrations take 1–1.5 years, plus plant inspections, totaling close to 2.5 years before they come through. This makes the injectable facility a slow-burn contributor to exports.
Hitesh Windlass: "we know that the quality of the facility will be a very big strategic advantage going forward in the future in injectables."
Capacity & Capital Allocation
- Existing setup can deliver ₹650–700 cr, stretchable to ₹750 cr: Internal enhancements, bottleneck reduction, and incremental expansion within the existing framework are underway. Management is confident capacity will not stifle growth.
- Three workstreams for the next leg: (1) unlocking inefficiencies and reducing bottlenecks, (2) adding capacity within the existing framework, (3) adding a new site for the longer term (three to four years). No timeline was given for an update.
- Inorganic dosage-form expansion on the table: Management wants to add dosage forms and is looking for opportunities, but will not build another plant from scratch. The priority is to make injectables profitable first, then pursue acquisitions where a business is already ready.
- Geographic preference is local: Organic expansion will stay in Dehradun. Inorganically, management is not averse to anywhere else within India.
Exports: Slow-Build Story
- Growth expected, but a longer incubation: The company is adding products to existing markets, working with existing distributors, spreading into neighboring markets, and opening new ones. Customer excitement exists around the injectable facility.
- Registration timelines stretch to 2.5 years: The process takes almost 1–1.5 years for registrations, plus plant inspections, adding another year. This makes export growth a gradual, back-end-loaded story.
Hitesh Windlass: "it takes almost one, one and a half year, and then plant inspections. So, another, close to, two and a half"
Margin & Cost Philosophy
- Margin improvement through volume and efficiency: The business is cost-plus in nature; margin expansion will come from volumes and the ability to create efficiencies, some of which get passed to customers.
- Employee cost treated as investment, not leakage: The Q3 increase from ESOPs, leadership hires, and variable pay is seen as motivation and capacity-building that has already supported margin delivery.
- Schedule M as a quality-cost anchor: Management frames compliance not as a cost burden but as a relationship-strengthening tailwind that will benefit the business over time.
Hitesh Windlass: "We have to be able to stand up and say that every product in our facility can be taken by our own children, right?"
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Injectable facility commercialization | Commercial production readiness | End of FY24 |
| Injectable facility P&L assessment | Evaluate capacity utilization, turnover, bottom line | Three quarters into FY25 |
| Trade generics growth ceiling | No fundamental limitation on growth rate | Until ~₹300 cr revenue |
| Capacity ceiling (existing setup) | Can deliver ₹650–700 cr, stretchable to ₹750 cr with incremental internal expansion | Current |
| Export registration cycle | Registrations plus plant inspections | ~2.5 years from initiation |
| Inorganic dosage-form expansion | Looking for opportunities; will not build another plant from scratch | After injectables become profitable |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue | ₹162 cr, +36% YoY |
| Revenue (9M FY24) | ₹460 cr, +23% YoY |
| EBITDA | ₹20 cr, +46% YoY |
| EBITDA (9M FY24) | ₹56 cr, +28% YoY |
| PAT | ₹15 cr, +64% YoY |
| PAT (9M FY24) | ₹41 cr, +32% YoY |
| EPS | ₹7.26, +71% YoY |
| EPS (9M FY24) | ₹19.79, +38% YoY; surpassed full FY23 annual EPS of ₹19.7 |
| Generic Formulation CDMO revenue | ₹125.5 cr, +44% YoY |
| Domestic Trade Generics & Institutional revenue | ₹28.5 cr, +19% YoY |
| Export revenue (9M FY24) | ₹18.5 cr, +44% YoY |
| IPM volume growth (9M FY24) | 1%, with price increase of 4% driving overall IPM growth of 8% |
| Top 10 customer concentration | ~40% of revenue |
| Top 20 customer concentration | ~45% of revenue |
| Existing facility revenue capacity | ₹700 cr to ₹750 cr with incremental internal expansion |